Butyl benzyl phthalate appears as a clear colorless liquid with a mild odor. Primary hazard is to the environment. Immediate steps should be taken to limit spread to the environment. Easily penetrates the soil to contaminate groundwater and nearby waterways.
颜色/状态：
Clear, oil liquid
气味：
Slight odor
味道：
Bitter
熔点：
-35 °C
蒸汽密度：
10.8 (NTP, 1992) (Relative to Air)
蒸汽压力：
8.25X10-6 mm Hg at 25 °C
稳定性/保质期：
与大多数树脂有良好的相容性，具有较强的溶剂化作用。
自燃温度：
425 °C
分解：
When heated to decomposition, it emits acrid smoke and irritating fumes.
BBP was not found in the bile, but monobutyl glucuronide and monobenzyl phthalate glucuronide (26 and 13% of the dose, respectively) and trace amounts of free monoesters (2% of the dose) and unidentified metabolites (14% of the dose) were present. Although BBP is an asymetrical diester with the potential of forming equal amounts of monobutyl phthalate and monobenzyl phthalate, larger quantities of monobutyl phthalate were formed (monobutyl phthalate= 44% vs monobenzyl phthalate= 16% of the dose). ...
The urinary monoester metabolites of seven commonly used phthalates /were measured/ in approximately 2,540 samples collected from participants of the National Health and Nutrition Examination Survey (NHANES), 1999-2000, who were greater than or equal to 6 years of age. ... Detectable levels of metabolites monoethyl phthalate (MEP), monobutyl phthalate (MBP), monobenzyl phthalate (MBzP), and mono-(2-ethylhexyl) phthalate (MEHP) /were found/ in > 75% of the samples, suggesting widespread exposure in the United States to diethyl phthalate, dibutyl phthalate or diisobutylphthalate, benzylbutyl phthalate, and di-(2-ethylhexyl) phthalate, respectively. ... Monoisononyl phthalate, mono-cyclohexyl phthalate, and mono-n-octyl phthalate /were detected infrequently/, suggesting that human exposures to di-isononyl phthalate, dioctylphthalate, and dicyclohexyl phthalate, respectively, are lower than those listed above, or the pathways, routes of exposure, or pharmacokinetic factors such as absorption, distribution, metabolism, and elimination are different. Non-Hispanic blacks had significantly higher concentrations of MEP than did Mexican Americans and non-Hispanic whites. Compared with adolescents and adults, children had significantly higher levels of MBP, MBzP, and MEHP but had significantly lower concentrations of MEP. Females had significantly higher concentrations of MEP and MBzP than did males, but similar MEHP levels. Of particular interest, females of all ages had significantly higher concentrations of the reproductive toxicant MBP than did males of all ages; however, women of reproductive age (i.e., 20-39 years of age) had concentrations similar to adolescent girls and women 40 years of age...
Three groups of eight volunteers were administered stable isotope-labelled ... benzylbutylphthalate. ... For benzylbutylphthalate, 67% and 78% was eliminated as monobenzylphthalate and only 6% (measured for the high dose only) was eliminated as monobutylphthalate. ...
n-Butyl benzyl phthalate (BBP) ... has been orally administered to female Wistar rats with four doses (150, 475, 780 and 1500 mg/kg body weight/day) for 3 consecutive days. Metabolites recovered in urine were analyzed by gas chromatography-mass spectrometry (GC-MS) after 24, 48 and 72 hours. Six metabolites were identified. Mono-n-butyl phthalate (MBuP) and mono-n-benzyl phthalate (MBeP) represented respectively 29-34% and 7-12% of the total recovered metabolites. Hippuric acid, the main metabolite of benzoic acid, represented the second major metabolite (51-56%). Phthalic acid, benzoic acid and an omega-oxidized metabolite of MBuP were also recovered in urine but in small quantities. BBP was never identified in urine. Total urinary metabolites recovery represented 56% of the dose administered in the first 24 hours. However, total recovery decreased when the dose increases (43% at 780 mg/kg body weight/day, only 30% at 1500 mg/kg body weight/day). Whatever the time was, BBP metabolites recovered in urine were all present and in the same proportions for the two lowest doses. Discrepancy in metabolites quantities expressed as percentages of the dose observed in urine of rat treated with the highest BBP dose disappeared with time as MBuP, MBeP and hippuric acid recovery has significantly increased at day 3. ...
Phthalate esters are first hydrolyzed to their monoester derivative. Once formed, the monoester derivative can be further hydrolyzed in vivo to phthalic acid or conjugated to glucuronide, both of which can then be excreted. The terminal or next-to-last carbon atom in the monoester can also be oxidized to an alcohol, which can be excreted as is or first oxidized to an aldehyde, ketone, or carboxylic acid. The monoester and oxidative metabolites are excreted in the urine and faeces. (A2884)
IDENTIFICATION AND USE: Butyl benzyl phthalate (BBP) is a clear oily liquid that is used as a plasticizer mainly in polyvinyl chloride for vinyl floor tile, vinyl foams and carpet backing and in cellulose plastics and polyurethane. HUMAN EXPOSURE AND TOXICITY: BBP was not observed to be a primary irritant or sensitizer in skin patch tests with volunteers. Prenatal exposure to BBP may influence the risk of developing eczema in early childhood. BBP was also positively associated with airway inflammation in children. BBP was positive in E-Screen assay used to measure the proliferation of MCF-7 cells, a human breast cancer cell line. In another study proteomic changes in proteins secreted by human hepatocellular carcinomas (HepG2) cells exposed to BBP were evaluated. These proteins were found to be involved in apoptosis, signaling, tumor progression, energy metabolism, and cell structure and motility. BBP treatment of plasmacytoid DC cells suppressed IFN-gamma but enhanced IL-13 production by CD4+ T cells. ANIMAL STUDIES: The acute toxicity of this compound is low, with oral LD50 values in rats being greater than 2 g/kg body weight. Target organs following acute exposure include the hematological and central nervous systems. Repeated dose toxicity studies of this compound in the rat show decreases in body weight gain and increases in organ to body weight ratios, particularly for the kidney and liver. Histopathological effects on the pancreas and kidney and hematological effects have also been observed. At higher doses, degenerative effects on the testes and, occasionally histopathological effects on the liver have been reported. In specialized investigations, peroximal proliferation in the liver has been noted. The chronic toxicity and carcinogenicity of BBP bioassays in rats and mice, indicated that there was some evidence of carcinogenicity in male rats, based on an increased incidence of pancreatic tumors, and equivocal evidence in female rats, based on marginal increases in pancreatic and bladder tumors. Dietary restriction prevented full expression of the pancreatic tumors. There was no evidence for the carcinogenicity of BBP in mice. BBP is not genotoxic. In a range of studies, including those designed to investigate the reproductive effects of BBP on the testes and endocrine hormone in male rats, a modified mating protocol and a one generation study, adverse effects on the testes and, consequently fertility have generally been observed only at doses higher than those that induce effects on other organs (such as the kidney and liver), although decreases in sperm counts have been observed at doses similar to those that induce effects in the kidney and liver. Reduction in testes weight and daily sperm production in the offspring were reported at relatively low level in rats exposed in utero and during lactation. Neither BBP nor its principal metabolites have been uteritrophic in vivo in rats or mice, In several well conducted studies in rats and mice, butyl benzyl phthalate induced marked developmental effects, but only at dose levels that induce significant maternal toxicity. BBP administration disrupts normal learning and social behavior in rats, and these effects could be related to alterations of amygdala function. ECOTOXICITY STUDIES: A range of toxicity tests with aquatic organisms has indicated the adverse effects occur at exposure concentrations greater than 100 ug/L. Behavioral changes in fish were noted after sublethal BBP exposure.
Phthalate esters are endocrine disruptors. They decrease foetal testis testosterone production and reduce the expression of steroidogenic genes by decreasing mRNA expression. Some phthalates have also been shown to reduce the expression of insulin-like peptide 3 (insl3), an important hormone secreted by the Leydig cell necessary for development of the gubernacular ligament. Animal studies have shown that these effects disrupt reproductive development and can cause a number of malformations in affected young. (A2883)
CLASSIFICATION: C; possible human carcinogen. BASIS FOR CLASSIFICATION: Based on statistically significant increase in mononuclear cell leukemia in female rats; the response in male rats was inconclusive and there was no such response in mice. HUMAN CARCINOGENICITY DATA: None. ANIMAL CARCINOGENICITY DATA: Limited.
Evaluation: There is inadequate evidence in humans for the carcinogenicity of butyl benzyl phthalate. There is limited evidence in experimental animals for the carcinogenicity of butyl benzyl phthalate. Overall evaluation: Butyl benzyl phthalate is not classifiable as to its carcinogenicity to humans (Group 3).
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌物分类
国际癌症研究机构致癌物：丁基苯基邻苯二甲酸酯
IARC Carcinogenic Agent:Butyl benzyl phthalate
来源:International Agency for Research on Cancer (IARC)
This study examined the extent of dermal absorption of a series of phthalate diesters in the rat. Those tested were dimethyl, diethyl, dibutyl, diisobutyl, dihexyl, di(2-ethylhexyl), diisodecyl, and benzyl butyl phthalate. Hair from a skin area (1.3 cm in diameter) on the back of male F344 rats was clipped, the 14C-phthalate diester was applied in a dose of 157 umol/kg, and the area of application was covered with a perforated cap. The rat was restrained and housed for 7 days in a metabolic cage that allowed separate collection of urine and feces. Urine and feces were collected every 24 hr, and the amount of carbon-14 excreted was taken as an index of the percutaneous absorption. At 24 hr, diethyl phthalate showed the greatest excretion (26%). As the length of the alkyl side chain increased, the amount of carbon-14 excreted in the first 24 hr decreased significantly. The cumulative percentage dose excreted in 7 days was greatest for diethyl, dibutyl, and diisobutyl phthalate, about 50-60% of the applied 14C; and intermediate (20-40%) for dimethyl, benzyl butyl, and dihexyl phthalate. Urine was the major route of excretion of all phthalate diesters except for diisodecyl phthalate. This compound was poorly absorbed and showed almost no urinary excretion. After 7 days, the percentage dose for each phthalate that remained in the body was minimal and showed no specific tissue distribution. Most of the unexcreted dose remained in the area of application. These data show that the structure of the phthalate diester determines the degree of dermal absorption. Absorption maximized with diethyl phthalate and then decreased significantly as the alkyl side chain length increased.
... Male Fischer-344 rats were dosed with (14)C-labeled butyl benzyl phthalate (BBP) at 2, 20, 200, or 2000 mg/kg orally or 20 mg/kg iv to detect the effects of dose on rates and routes of excretion. In 24 hr, 61-74% of the dose was excreted in the urine and 13-19% in the feces at 2-200 mg/kg. At 2000-mg/kg, 16% of the (14)C was excreted in the urine and 57% in the feces. Urinary (14)C was composed of monophthalate glucuronides derivatives (MP: 10-42% of the dose) and monophthalate glucuronides (2-21% of the dose). At 4 hr after iv administration of BBP (20 mg/kg), 53-58% of the dose was excreted in the bile of anesthetized rats. BBP was not found in the bile, but monobutyl glucuronide and monobenzyl phthalate glucuronide (26 and 13% of the dose, respectively) and trace amts of free monoesters (2% of the dose) and unidentified metabolites (14% of the dose) were present. ... The half-lives of BBP, MP, and total (14)C in blood (20 mg/kg, iv) were 10 min, 5.9 hr, and 6.3 hr, respectively. ...
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
静脉注射20 mg/kg的(14)C-BBP后，55%的剂量被排入胆汁中，34%被排入尿液中。
Following intravenous administration of 20 mg/kg of (14)C-BBP, 55% of the dose was excreted into bile and 34% was excreted into the urine.
Beagle dogs were given a 5 g/kg bw oral dose of butyl benzyl phthalate divided over a 4 hr period. Unchanged butyl benzyl phthalate in the feces comprised 88-91% of the dose. While butyl benzyl phthalate was not present in the urine, some 4.2% of the dose was present as phthalic acid
1.周国泰，化学危险品安全技术全书，化学工业出版社，1997 2.国家环保局有毒化学品管理办公室、北京化工研究院合编，化学品毒性法规环境数据手册，中国环境科学出版社.1992 3.Canadian Centre for Occupational Health and Safety,CHEMINFO Database.1998 4.Canadian Centre for Occupational Health and Safety, RTECS Database, 1989
[EN] HEMI-AMINAL ETHERS AND THIOETHERS OF N-ALKENYL CYCLIC COMPOUNDS<br/>[FR] ÉTHERS ET THIOÉTHERS HÉMIAMINAUX DE COMPOSÉS CYCLIQUES N-ALCÉNYLIQUES
申请人：ISP INVESTMENTS INC
公开号：WO2014116560A1
公开（公告）日：2014-07-31
Described herein are hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds that may be produced through a reaction comprising: (A) at least one first reactant represented by a structure (I), wherein X is a functionalized or unfunctionalized C1-C5 alkylene group optionally having one or more heteroatoms, and each R1, R2, and R3 is independently selected from the group consisting of hydrogen and functionalized and unfunctionalized alkyl groups optionally having one or more heteroatoms, and (B) at least one second reactant having at least one hydroxyl moiety or thiol moiety. The hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds may comprise a polymerizable moiety, in which case they may be left as-is or used to create homopolymers or non-homopolymers, or they may not comprise a polymerizable moiety. A wide variety of formulations may be created using the hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds, including personal care, oilfield, and construction formulations.
Described herein are methods for treating a blood vessel. In an embodiment, the method of treating a blood vessel comprises providing at least one manipulable tool in a blood vessel, depositing a non-solid polymerizable material into a deposition area of the vessel, wherein the polymerizable liquid hardens over time upon contact with blood in the blood vessel, and altering the shape of the polymerizable material while it hardens by manipulating the tool.
BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF
申请人：SENOMYX, INC.
公开号：US20160376263A1
公开（公告）日：2016-12-29
The present invention includes compounds and compositions known to modify the perception of bitter taste, and combinations of said compositions and compounds with additional compositions, compounds, and products. Exemplary compositions comprise one or more of the following: cooling agents; inactive drug ingredients; active pharmaceutical ingredients; food additives or foodstuffs; flavorants, or flavor enhancers; food or beverage products; bitter compounds; sweeteners; bitterants; sour flavorants; salty flavorants; umami flavorants; plant or animal products; compounds known to be used in pet care products; compounds known to be used in personal care products; compounds known to be used in home products; pharmaceutical preparations; topical preparations; cannabis-derived or cannabis-related products; compounds known to be used in oral care products; beverages; scents, perfumes, or odorants; compounds known to be used in consumer products; silicone compounds; abrasives; surfactants; warming agents; smoking articles; fats, oils, or emulsions; and/or probiotic bacteria or supplements.
Heterocylic fluoroalkenyl thioethers and the use thereof as pesticides (IV)
申请人：——
公开号：US20030187259A1
公开（公告）日：2003-10-02
The present invention relates to novel heterocyclic fluoroalkenyl thioethers of the formula (I)
1
in which
m represents integers from 3 to 10,
n represents 0, 1 or 2 and
Het represents the following, in each case optionally substituted, groupings:
2
and to processes for their preparation and to their use as pesticides.
Use of riboflavin and flavin derivatives as chitinase inhibitors
申请人：——
公开号：US20030191091A1
公开（公告）日：2003-10-09
The invention relates to the use of riboflavin and of flavin derivatives with chitinase-inhibitory action for controlling arthropods, nematodes and chitin-containing fungi.
